|
|
|
Technology The receptors
under investigation at Orphagen Pharmaceuticals have been implicated in
autoimmune disease, sleep-wake disorders, metabolic disease, and mood
disorders. High throughput screening has yielded modulators with properties
suitable for medicinal chemistry exploration and lead molecules derived from
these are under intensive investigation. Therapeutic Areas Autoimmune
disease. Orphagen has pioneered the
discovery of selective inhibitors of Th-17 cells, a novel class of T
lymphocytes implicated in psoriasis, Crohn’s Disease, rheumatoid arthritis,
and multiple sclerosis. Circadian
Regulation. Orphagen is exploring
targets that control the body’s endogenous day-night cycle (circadian rhythm)
in the brain. These targets have major potential for the treatment of
sleep-wake and mood disorders. Metabolic
Disease. Diabetes and hyperlipidemia
are major causes of morbidity and mortality in the U.S. Orphagen is investigating targets that
regulate glucose and lipid metabolism with potential as novel therapeutics in
this area.
|
|
|